Skip to main content
Erschienen in: Cancer Causes & Control 6/2007

01.08.2007 | Original Paper

Obesity and risk of non-Hodgkin lymphoma (United States)

verfasst von: Brian C.-H. Chiu, Lori Soni, Susan M. Gapstur, Angela J. Fought, Andrew M. Evens, Dennis D. Weisenburger

Erschienen in: Cancer Causes & Control | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Abstract

Objective

Few studies have explored the potential association between body mass index (BMI) and non-Hodgkin lymphoma (NHL) according to histologic subtypes, or have evaluated BMI at different periods in the subject’s life, and the results of these studies have been inconsistent.

Subjects

A population-based, case–control study of 387 patients with NHL and 535 controls conducted in Nebraska between 1999 and 2002.

Methods

Information on usual adult weight, weight at the ages 20–29, 40–49, and 60–69 years, height, physical activity, and other lifestyle factors was collected by telephone interview. A self-administered semi-quantitative food frequency questionnaire was used to collect dietary intake. Risk was estimated by odds ratios (ORs) and 95% confidence intervals (CIs), adjusting for age, total energy intake, physical activity, and other confounding factors.

Results

Higher adult BMI was associated with risk of NHL (OR = 1.4; 95% CI = 0.9–2.0) comparing the obese group (BMI ≥ 30.0 kg/m2) with the normal weight group (BMI = 18.5–24.9 kg/m2). The risk was higher for those who were class 2 obese (BMI ≥ 35.0 kg/m2, OR = 1.7; 95% CI = 1.0–2.9). The positive association was similar among men and women. An excess risk of NHL was associated with high BMI at ages 40–49 years (OR = 1.6; 95% CI = 1.0–2.5), and to a lesser extent, at ages 20–29 years (OR = 1.4; 95% CI = 0.8–2.5). Obesity at ages 40–49 years was also associated with a higher risk of small lymphocytic lymphoma (OR = 4.5; 95% CI = 1.5–13.3), diffuse large B-cell NHL (OR = 1.8; 95% CI = 0.9–3.9) and follicular NHL (OR = 1.8; 95% CI = 0.9–3.5).

Conclusion

Obesity is associated with risk of NHL overall. Obesity at ages 40–49 years is also associated with a higher risk of NHL overall, and particularly small lymphocytic, follicular, and diffuse large B-cell NHL.
Literatur
1.
Zurück zum Zitat Stallone DD (1994) The influence of obesity and its treatment on the immune system. Nutr Rev 52:37–50PubMed Stallone DD (1994) The influence of obesity and its treatment on the immune system. Nutr Rev 52:37–50PubMed
2.
Zurück zum Zitat Cerhan JR, Bernstein L, Severson RK et al (2005) Anthropometrics, physical activity, related medical conditions, and the risk of non-hodgkin lymphoma. Cancer Causes Control 16:1203–1214PubMedCrossRef Cerhan JR, Bernstein L, Severson RK et al (2005) Anthropometrics, physical activity, related medical conditions, and the risk of non-hodgkin lymphoma. Cancer Causes Control 16:1203–1214PubMedCrossRef
3.
Zurück zum Zitat Cerhan JR, Janney CA, Vachon CM et al (2002) Anthropometric characteristics, physical activity, and risk of non-Hodgkin’s lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective study. Am J Epidemiol 156:527–535PubMedCrossRef Cerhan JR, Janney CA, Vachon CM et al (2002) Anthropometric characteristics, physical activity, and risk of non-Hodgkin’s lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective study. Am J Epidemiol 156:527–535PubMedCrossRef
4.
Zurück zum Zitat Chang ET, Hjalgrim H, Smedby KE et al (2005) Body mass index and risk of malignant lymphoma in Scandinavian men and women. J Natl Cancer Inst 97:210–218PubMedCrossRef Chang ET, Hjalgrim H, Smedby KE et al (2005) Body mass index and risk of malignant lymphoma in Scandinavian men and women. J Natl Cancer Inst 97:210–218PubMedCrossRef
5.
Zurück zum Zitat Fernberg P, Odenbro A, Bellocco R, Boffetta P, Pawitan Y, Adami J (2006) Tobacco use, body mass index and the risk of malignant lymphomas–a nationwide cohort study in Sweden. Int J Cancer 118:2298–2302PubMedCrossRef Fernberg P, Odenbro A, Bellocco R, Boffetta P, Pawitan Y, Adami J (2006) Tobacco use, body mass index and the risk of malignant lymphomas–a nationwide cohort study in Sweden. Int J Cancer 118:2298–2302PubMedCrossRef
6.
Zurück zum Zitat Holly EA, Lele C, Bracci PM, McGrath MS (1999) Case–control study of non-Hodgkin’s lymphoma among women and heterosexual men in the San Francisco Bay Area, California. Am J Epidemiol 150:375–389PubMed Holly EA, Lele C, Bracci PM, McGrath MS (1999) Case–control study of non-Hodgkin’s lymphoma among women and heterosexual men in the San Francisco Bay Area, California. Am J Epidemiol 150:375–389PubMed
7.
Zurück zum Zitat MacInnis RJ, English DR, Hopper JL, Giles GG (2005) Body size and composition and the risk of lymphohematopoietic malignancies. J Natl Cancer Inst 97:1154–1157PubMedCrossRef MacInnis RJ, English DR, Hopper JL, Giles GG (2005) Body size and composition and the risk of lymphohematopoietic malignancies. J Natl Cancer Inst 97:1154–1157PubMedCrossRef
8.
Zurück zum Zitat Moller H, Mellemgaard A, Lindvig K, Olsen JH (1994) Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 30A:344–350PubMedCrossRef Moller H, Mellemgaard A, Lindvig K, Olsen JH (1994) Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 30A:344–350PubMedCrossRef
9.
Zurück zum Zitat Oh SW, Yoon YS, Shin SA (2005) Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 23:4742–4754PubMedCrossRef Oh SW, Yoon YS, Shin SA (2005) Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 23:4742–4754PubMedCrossRef
10.
Zurück zum Zitat Pan SY, Johnson KC, Ugnat AM, Wen SW, Mao Y (2004) Association of obesity and cancer risk in Canada. Am J Epidemiol 159:259–268PubMedCrossRef Pan SY, Johnson KC, Ugnat AM, Wen SW, Mao Y (2004) Association of obesity and cancer risk in Canada. Am J Epidemiol 159:259–268PubMedCrossRef
11.
Zurück zum Zitat Pan SY, Mao Y, Ugnat AM (2005) Physical activity, obesity, energy intake, and the risk of non-Hodgkin’s lymphoma: a population-based case–control study. Am J Epidemiol 162:1162–1173PubMedCrossRef Pan SY, Mao Y, Ugnat AM (2005) Physical activity, obesity, energy intake, and the risk of non-Hodgkin’s lymphoma: a population-based case–control study. Am J Epidemiol 162:1162–1173PubMedCrossRef
12.
Zurück zum Zitat Rapp K, Schroeder J, Klenk J et al (2005) Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. Br J Cancer 93:1062–1067PubMedCrossRef Rapp K, Schroeder J, Klenk J et al (2005) Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. Br J Cancer 93:1062–1067PubMedCrossRef
13.
Zurück zum Zitat Samanic C, Chow WH, Gridley G, Jarvholm B, Fraumeni JF Jr. (2006) Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control 17:901–909PubMedCrossRef Samanic C, Chow WH, Gridley G, Jarvholm B, Fraumeni JF Jr. (2006) Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control 17:901–909PubMedCrossRef
14.
Zurück zum Zitat Samanic C, Gridley G, Chow WH, Lubin J, Hoover RN, Fraumeni JF Jr. (2004) Obesity and cancer risk among white and black United States veterans. Cancer Causes Control 15:35–43PubMedCrossRef Samanic C, Gridley G, Chow WH, Lubin J, Hoover RN, Fraumeni JF Jr. (2004) Obesity and cancer risk among white and black United States veterans. Cancer Causes Control 15:35–43PubMedCrossRef
15.
Zurück zum Zitat Skibola CF, Holly EA, Forrest MS et al (2004) Body mass index, leptin and leptin receptor polymorphisms, and non-hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 13:779–786PubMed Skibola CF, Holly EA, Forrest MS et al (2004) Body mass index, leptin and leptin receptor polymorphisms, and non-hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 13:779–786PubMed
16.
Zurück zum Zitat Willett EV, Skibola CF, Adamson P et al (2005) Non-Hodgkin’s lymphoma, obesity and energy homeostasis polymorphisms. Br J Cancer 93:811–816PubMedCrossRef Willett EV, Skibola CF, Adamson P et al (2005) Non-Hodgkin’s lymphoma, obesity and energy homeostasis polymorphisms. Br J Cancer 93:811–816PubMedCrossRef
17.
Zurück zum Zitat Wolk A, Gridley G, Svensson M et al (2001) A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 12:13–21PubMedCrossRef Wolk A, Gridley G, Svensson M et al (2001) A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 12:13–21PubMedCrossRef
18.
Zurück zum Zitat Bahl S, Cotterchio M, Kreiger N, Klar N (2004) Antidepressant medication use and non-Hodgkin’s lymphoma risk: no association. Am J Epidemiol 160:566–575PubMedCrossRef Bahl S, Cotterchio M, Kreiger N, Klar N (2004) Antidepressant medication use and non-Hodgkin’s lymphoma risk: no association. Am J Epidemiol 160:566–575PubMedCrossRef
19.
Zurück zum Zitat Chiu BC, Gapstur SM, Greenland P, Wang R, Dyer A (2006) Body mass index, abnormal glucose metabolism, and mortality from hematopoietic cancer. Cancer Epidemiol Biomarkers Prev 15:2348–2354PubMedCrossRef Chiu BC, Gapstur SM, Greenland P, Wang R, Dyer A (2006) Body mass index, abnormal glucose metabolism, and mortality from hematopoietic cancer. Cancer Epidemiol Biomarkers Prev 15:2348–2354PubMedCrossRef
20.
Zurück zum Zitat Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638PubMedCrossRef Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638PubMedCrossRef
21.
Zurück zum Zitat Chiu BC, Weisenburger DD (2003) An update of the epidemiology of non-Hodgkin’s lymphoma. Clin Lymphoma 4:161–168PubMedCrossRef Chiu BC, Weisenburger DD (2003) An update of the epidemiology of non-Hodgkin’s lymphoma. Clin Lymphoma 4:161–168PubMedCrossRef
22.
Zurück zum Zitat Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 107:265–276PubMedCrossRef Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 107:265–276PubMedCrossRef
23.
Zurück zum Zitat Chiu BC, Kolar C, Gapstur SM, Lawson T, Anderson JR, Weisenburger DD (2005) Association of NAT and GST polymorphisms with non-Hodgkin’s lymphoma: a population-based case–control study. Br J Haematol 128:610–615PubMedCrossRef Chiu BC, Kolar C, Gapstur SM, Lawson T, Anderson JR, Weisenburger DD (2005) Association of NAT and GST polymorphisms with non-Hodgkin’s lymphoma: a population-based case–control study. Br J Haematol 128:610–615PubMedCrossRef
24.
Zurück zum Zitat Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) World Health Organization classification of tumors. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. IARC Press, Lyon Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) World Health Organization classification of tumors. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. IARC Press, Lyon
25.
Zurück zum Zitat Waksberg J (1978) Sampling methods for random digit dialing. JASA 73:40–46 Waksberg J (1978) Sampling methods for random digit dialing. JASA 73:40–46
26.
Zurück zum Zitat Hartge P, Brinton LA, Rosenthal JF, Cahill JI, Hoover RN, Waksberg J (1984) Random digit dialing in selecting a population-based control group. Am J Epidemiol 120:825–833PubMed Hartge P, Brinton LA, Rosenthal JF, Cahill JI, Hoover RN, Waksberg J (1984) Random digit dialing in selecting a population-based control group. Am J Epidemiol 120:825–833PubMed
27.
Zurück zum Zitat Block G, Coyle LM, Hartman AM, Scoppa SM (1994) Revision of dietary analysis software for the health habits and history questionnaire. Am J Epidemiol 139:1190–1196PubMed Block G, Coyle LM, Hartman AM, Scoppa SM (1994) Revision of dietary analysis software for the health habits and history questionnaire. Am J Epidemiol 139:1190–1196PubMed
28.
Zurück zum Zitat Physical status: the use and interpretation of anthropometry: report of a WHO Expert Committee (1995) World Health Organization, 1–452 Physical status: the use and interpretation of anthropometry: report of a WHO Expert Committee (1995) World Health Organization, 1–452
29.
Zurück zum Zitat Breslow NE, Day NE (1993) Statistical methods in cancer research. Vol 1. The analysis of case-control studies. IARC Sci Publications, No. 82, Oxford University Press, Inc., New York Breslow NE, Day NE (1993) Statistical methods in cancer research. Vol 1. The analysis of case-control studies. IARC Sci Publications, No. 82, Oxford University Press, Inc., New York
30.
Zurück zum Zitat Maldonado G, Greenland S (1993) Simulation study of confounder-selection strategies. Am J Epidemiol 138:923–936PubMed Maldonado G, Greenland S (1993) Simulation study of confounder-selection strategies. Am J Epidemiol 138:923–936PubMed
31.
Zurück zum Zitat Barba C, Cavalli-Sforza T, Cutter J, Darnton-Hill I, Deurenberg P, Gill T, James P, Ko G, Deurenberg-Yap M (2004) Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363:157–163CrossRef Barba C, Cavalli-Sforza T, Cutter J, Darnton-Hill I, Deurenberg P, Gill T, James P, Ko G, Deurenberg-Yap M (2004) Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363:157–163CrossRef
32.
Zurück zum Zitat Clarke CA, Undurraga DM, Harasty PJ, Glaser SL, Morton LM, Holly EA (2006) Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev 15:630–638PubMedCrossRef Clarke CA, Undurraga DM, Harasty PJ, Glaser SL, Morton LM, Holly EA (2006) Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev 15:630–638PubMedCrossRef
33.
Zurück zum Zitat Whittemore AS, Paffenbarger RS, Jr. Anderson K, Lee JE (1985) Early precursors of site-specific cancers in college men and women. J Natl Cancer Inst 74:43–51PubMed Whittemore AS, Paffenbarger RS, Jr. Anderson K, Lee JE (1985) Early precursors of site-specific cancers in college men and women. J Natl Cancer Inst 74:43–51PubMed
34.
Zurück zum Zitat Kumar NB, Lyman GH, Allen K, Cox CE, Schapira DV (1995) Timing of weight gain and breast cancer risk. Cancer 76:243–249PubMedCrossRef Kumar NB, Lyman GH, Allen K, Cox CE, Schapira DV (1995) Timing of weight gain and breast cancer risk. Cancer 76:243–249PubMedCrossRef
35.
Zurück zum Zitat Swanson CA, Potischman N, Wilbanks GD et al (1993) Relation of endometrial cancer risk to past and contemporary body size and body fat distribution. Cancer Epidemiol Biomarkers Prev 2:321–327PubMed Swanson CA, Potischman N, Wilbanks GD et al (1993) Relation of endometrial cancer risk to past and contemporary body size and body fat distribution. Cancer Epidemiol Biomarkers Prev 2:321–327PubMed
36.
Zurück zum Zitat Dandona P, Aljada A, Bandyopadhyay A (2004) Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25:4–7PubMedCrossRef Dandona P, Aljada A, Bandyopadhyay A (2004) Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25:4–7PubMedCrossRef
37.
Zurück zum Zitat Rothman N, Skibola CF, Wang SS et al (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the interlymph consortium. Lancet Oncol 7:27–38PubMedCrossRef Rothman N, Skibola CF, Wang SS et al (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the interlymph consortium. Lancet Oncol 7:27–38PubMedCrossRef
38.
Zurück zum Zitat Drewnowski A, Kurth C, Holden-Wiltse J, Saari J (1992) Food preferences in human obesity: carbohydrates versus fats. Appetite 18:207–221PubMedCrossRef Drewnowski A, Kurth C, Holden-Wiltse J, Saari J (1992) Food preferences in human obesity: carbohydrates versus fats. Appetite 18:207–221PubMedCrossRef
39.
Zurück zum Zitat Chiu BC, Cerhan JR, Folsom AR et al (1996) Diet and risk of non-Hodgkin lymphoma in older women. JAMA 275:1315–1321PubMedCrossRef Chiu BC, Cerhan JR, Folsom AR et al (1996) Diet and risk of non-Hodgkin lymphoma in older women. JAMA 275:1315–1321PubMedCrossRef
40.
Zurück zum Zitat Zheng T, Holford TR, Leaderer B et al (2004) Diet and nutrient intakes and risk of non-Hodgkin’s lymphoma in connecticut women. Am J Epidemiol 159:454–466PubMedCrossRef Zheng T, Holford TR, Leaderer B et al (2004) Diet and nutrient intakes and risk of non-Hodgkin’s lymphoma in connecticut women. Am J Epidemiol 159:454–466PubMedCrossRef
41.
Zurück zum Zitat Stevens J, Keil JE, Waid LR, Gazes PC (1990) Accuracy of current, 4-year, and 28-year self-reported body weight in an elderly population. Am J Epidemiol 132:1156–1163PubMed Stevens J, Keil JE, Waid LR, Gazes PC (1990) Accuracy of current, 4-year, and 28-year self-reported body weight in an elderly population. Am J Epidemiol 132:1156–1163PubMed
42.
Zurück zum Zitat Palta M, Prineas RJ, Berman R, Hannan P (1982) Comparison of self-reported and measured height and weight. Am J Epidemiol 115:223–230PubMed Palta M, Prineas RJ, Berman R, Hannan P (1982) Comparison of self-reported and measured height and weight. Am J Epidemiol 115:223–230PubMed
43.
Zurück zum Zitat Nomura A, Heilbrun LK, Stemmermann GN (1985) Body mass index as a predictor of cancer in men. J Natl Cancer Inst 74:319–323PubMed Nomura A, Heilbrun LK, Stemmermann GN (1985) Body mass index as a predictor of cancer in men. J Natl Cancer Inst 74:319–323PubMed
44.
Zurück zum Zitat Kuskowska-Wolk A, Karlsson P, Stolt M, Rossner S (1989) The predictive validity of body mass index based on self-reported weight and height. Int J Obes 13:441–453PubMed Kuskowska-Wolk A, Karlsson P, Stolt M, Rossner S (1989) The predictive validity of body mass index based on self-reported weight and height. Int J Obes 13:441–453PubMed
46.
Zurück zum Zitat Bureau USC. Census 2000 Summary File 3, Matrices P18, P19, P21, P22, P24, P36, P37, P39, P42, PCT8, PCT16, PCT17, and PCT19:http://factfinder.census.gov/servlet/QTTable?_bm = y&-geo_id = 04000US04031&-qr_name = DEC_02000_SF04003_U_DP04002&-ds_name = DEC_02000_SF04003_U Bureau USC. Census 2000 Summary File 3, Matrices P18, P19, P21, P22, P24, P36, P37, P39, P42, PCT8, PCT16, PCT17, and PCT19:http://​factfinder.​census.​gov/​servlet/​QTTable?​_​bm = y&-geo_id = 04000US04031&-qr_name = DEC_02000_SF04003_U_DP04002&-ds_name = DEC_02000_SF04003_U
Metadaten
Titel
Obesity and risk of non-Hodgkin lymphoma (United States)
verfasst von
Brian C.-H. Chiu
Lori Soni
Susan M. Gapstur
Angela J. Fought
Andrew M. Evens
Dennis D. Weisenburger
Publikationsdatum
01.08.2007
Verlag
Kluwer Academic Publishers
Erschienen in
Cancer Causes & Control / Ausgabe 6/2007
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-007-9013-9

Weitere Artikel der Ausgabe 6/2007

Cancer Causes & Control 6/2007 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.